MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Knowledge paper highlights biosimilars, biologics, AI-driven drug discovery and regulatory excellence as key growth drivers for the next phase of India's pharma expansion
The award places the company in the top 5% globally
Mohit Yadav reaffirmed government's commitment to improve competitiveness, enhance export capabilities and support the country's transition from volume-driven to value-driven exports
Recognition places pharmaceutical excipients leader among the top 5% of companies globally, highlighting progress in emissions reduction, responsible sourcing, and sustainable supply chain practices
Strategic shift from Italy to India strengthens supply chain resilience, expands capacity and enhances sustainability for the growing global UDCA market
Seasoned governance expert and board leader brings extensive experience in strategic oversight, risk management, and corporate governance across multiple sectors
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
Derived from rice bran wax, Licocare RBW products offer a renewable solution with a substantially lower carbon footprint than conventional montan waxes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
